|
Debiopharm Group (Debiopharm) is a global biopharmaceutical group of companies comprising Debiopharm S.A., Debio R.P. S.A. (Recherche Pharmaceutique), Debioclinic S.A. and the two financial arms Debiomanagement S.A. and Debioinnovation S.A. The group applies scientific and clinical expertise to address unmet medical needs through the in-licensing of promising biologics and small molecules, the clinical development of the same and the out-licensing for commercialisation. The group is family owned. The company has developed triptorelin under the brandnames Decapeptyl/Trelstar/Pamorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer and ovarian cancer, and under the brandnames Moapar/Salvacyl for the treatment of severe sexual deviations and of oxaliplatin (Eloxatin/Elplat) for the treatment of colorectal cancer. For thirty years Debiopharm Group has established alliances with leading biotech, pharmaceutical and start-up companies as well as with academic institutions. Sanofi-Aventis, Ipsen Pharma, Novartis, Curis, MSM Protein Technologies, Mercury Therapeutics, École Polytechnique Fédérale de Lausanne (EPFL) are a few examples of Debiopharm partners. ==History== In 1979, Dr. Rolland-Yves Mauvernay founded Debiopharm Group. In 1981, the laboratory Cytotech was created in Martigny and a few years later became Debio R.P.. The company first worked on interferon and in 1982, started to focus on triptorelin after acquiring the rights to its development from Tulane University. The first license to market triptorelin was obtained in France, in 1986. In 1989, Debiopharm in-licensed oxaliplatin from Nagoya City University. The drug was first approved in Europe, in 1996. Debioclinic S.A. was founded in 1993. In September 2004, after having occupied various locations in Lausanne, Debiopharm Group moved its headquarters to its current situation. Today, the Debiopharm Group consists of 340 employees from 18 different countries and is supported by 400 external advisers. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Debiopharm」の詳細全文を読む スポンサード リンク
|